RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
E-Therapeutics Stock

E-Therapeutics Stocks 2024

E-Therapeutics Stocks

537.35 M

Ticker

ETX.L

ISIN

GB00B2823H99

WKN

A0M8VQ

In 2024, E-Therapeutics had 537.35 M outstanding stocks, a 0% change from the 537.35 M stocks in the previous year.

The E-Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined GBP)
2024e537.35
2023537.35
2022488.34
2021373.22
2020268.86
2019268.58
2018268.46
2017267.06
2016264.42
2015264.15
2014254.4
2013138.16
2012131.01
201165.84
201060.11
200955.71
200851.54
200755.71
200655.71
200555.71

E-Therapeutics shares outstanding

The number of shares was E-Therapeutics in 2023 — This indicates how many shares 537.346 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue E-Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates E-Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of E-Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating E-Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

E-Therapeutics Aktienanalyse

What does E-Therapeutics do?

E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It was founded in 2003 by Prof. Malcolm Young and has made significant progress in the field of drug development since then. The company has always aimed for an innovative business model focused on identifying new compounds through computer simulations. E-Therapeutics has developed a unique platform called Network Pharmacology, which simulates complex biological systems and identifies potential drug candidates. The platform uses mathematical models and artificial intelligence to identify molecules that can have a positive effect on specific cells. E-Therapeutics' business model is designed to collaborate with partners in developing new drug candidates. The company offers its platform and expertise to support customers in identifying new chemical compounds. E-Therapeutics works closely with top pharmaceutical companies to advance the development of new drugs. E-Therapeutics is divided into three divisions, each focusing on different areas of medical drug research: 1. Oncology division: This division focuses on developing drugs for the treatment of cancer. E-Therapeutics uses its unique platform to develop targeted therapies tailored to the individual needs of the patient. The platform can also be used to identify new biomarkers and potential therapeutics for a variety of cancer diseases. 2. Neurology division: E-Therapeutics' neurology division focuses on identifying drugs for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and Huntington's. E-Therapeutics' platform has already been used to identify new drug candidates that could have a positive effect on the symptoms of these diseases. 3. Infectious Diseases division: E-Therapeutics' infectious diseases division focuses on the development of drugs for the treatment of infectious diseases such as HIV and influenza. E-Therapeutics uses its platform to identify new compounds that have the potential to fight infections and prevent the spread of diseases. E-Therapeutics has a pipeline of products targeting different medical fields. One promising product is ETS-101, a novel drug candidate for the treatment of pain. ETS-101 has already shown positive results in preclinical studies and is currently in phase 1 studies. Another promising product is ETS-6103, being developed for the treatment of depression. ETS-6103 has been successfully tested in preclinical studies and is currently in phase 2 clinical development. In summary, E-Therapeutics focuses on developing drugs that work at a biological level. The company's innovative business model, unique platform, and collaboration with top pharmaceutical companies make it a key player in medical drug research. With a pipeline of promising products, E-Therapeutics has the potential to change the face of medical drug research and advance the world of medicine. Answer: E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It focuses on identifying new compounds through computer simulations and has developed a unique platform called Network Pharmacology. The company collaborates with partners to develop new drug candidates and is divided into divisions focused on oncology, neurology, and infectious diseases. E-Therapeutics has a pipeline of promising products, including ETS-101 for pain treatment and ETS-6103 for depression treatment. It aims to advance medical drug research and contribute to the field of medicine. E-Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating E-Therapeutics's Shares Outstanding

E-Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in E-Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding E-Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in E-Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about E-Therapeutics stock

How many stocks are there of E-Therapeutics?

The current number of stocks of E-Therapeutics is 537.35 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of E-Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of E-Therapeutics evolved in recent years?

The number of shares of E-Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. E-Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of E-Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does E-Therapeutics pay?

Over the past 12 months, E-Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, E-Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of E-Therapeutics?

The current dividend yield of E-Therapeutics is .

When does E-Therapeutics pay dividends?

E-Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of E-Therapeutics?

E-Therapeutics paid dividends every year for the past 0 years.

What is the dividend of E-Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is E-Therapeutics located?

E-Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von E-Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of E-Therapeutics from 10/2/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did E-Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of E-Therapeutics in the year 2023?

In the year 2023, E-Therapeutics distributed 0 GBP as dividends.

In which currency does E-Therapeutics pay out the dividend?

The dividends of E-Therapeutics are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von E-Therapeutics

Our stock analysis for E-Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of E-Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.